A Study to Characterize the Pharmacokinetics, Pharmacodynamics, and Safety of Anifrolumab in Adult Type I Interferon Test High Systemic Lupus Erythematosus Subject With Active Skin Manifestations

Number of Participants With Antidrug Antibody (ADA)

Post-baseline ADA incidence based on the number of participants with Antidrug antibody (ADA)

Time frame: Baseline to Week 52

Number of Participants With Neutralizing Antibodies (nAb)

Incidence of detectable nAb in post-baseline ADA positive participants.

Time frame: Baseline to Week 52

Number AEs (Adverse Events) and SAEs (Serious Adverse Events), Including Adverse Events of Special Interest (AESI)

Number of participants with any AEs (Adverse events), any SAEs (serious adverse events), and any adverse events of special interest (AESI) are summarized. More details are reported in the Adverse Events section.

Time frame: Baseline to Week 52

Change From Baseline for Vital Signs

Change from baseline for vital signs.

Time frame: Baseline to Week 60

Change From Baseline for Physical Examination

Physical examination is reported as change from baseline in body weight.

Time frame: Baseline to Week 60

Change From Baseline for 12-lead ECG

The 12-lead ECG measurements were assessed by the investigators, and reported as normal, abnormal (not clinically significant \[NCS\]), abnormal (clinically significant \[CS\]), or not done.

Time frame: Baseline to Week 52

Value of Haemoglobin Blood Test to Detect Change From Baseline

Change from baseline in haemoglobin blood tests are reported.

Time frame: Baseline to Week 60

Value of Haematology Blood Tests to Detect Change From Baseline

Change from baseline in haematology blood tests (leucocytes \[particle concentration\], platelets \[particle concentration\]) are reported.

Time frame: Baseline to Week 60

Value of Protein-creatinine Urinalysis Test to Detect Change From Baseline

Change from baseline in protein-creatinine ratio urinalysis tests are reported.

Time frame: Baseline to Week 60

Value of Total Protein Urinalysis Test to Detect Change From Baseline

Change from baseline in total protein urinalysis tests are reported.

Time frame: Baseline to Week 60

Value of Clinical Chemistry Blood Tests to Detect Change From Baseline (Serum)

Change from baseline in clinical chemistry blood tests (Alanine Aminotransferase, Aspartate Aminotransferase) are reported.

Time frame: Baseline to Week 60

Value of Creatinine Clinical Chemistry Blood Tests to Detect Change From Baseline (Serum)

Change from baseline in clinical creatinine chemistry blood tests (serum) are reported.

Time frame: Baseline to Week 60

Value of Inflammatory Marker Panel Blood Tests to Detect Change From Baseline

Change from baseline in the Erythrocyte Sedimentation Rate (ESR) inflammatory marker is reported.

Time frame: Baseline to Week 60

Value of Autoantibody Blood Panel Blood Tests to Detect Change From Baseline

Change from baseline in Anti-Double Stranded DNA IgG (anti-dsDNA) is reported.

Time frame: Baseline to Week 60

Number of Participants With Positive Hepatitis B Core Antibody Post-baseline.

Change from screening in Hepatitis B core antibody was monitored during the study for participants tested positive at screening.

Time frame: Baseline to Week 60